title: AMPed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy.
abstract: Despite recent advances in the treatment for metastatic prostatic adenocarcinoma, clinical management of this tumor type remains a major challenge, and there is as of yet no durable cure for advanced disease. Developing pathways that could be co-targeted alongside the androgen receptor or that would otherwise thwart the development of the CRPC is a current translational and clinical priority. In this issue, a new study by Zadra et al identifies the energy sensor AMPK (5' AMP-activated kinase) as a viable therapeutic target in prostate cancer.
authors.affiliation: Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Schiewer
authors.forename: Karen E
authors.initials: KE
authors.lastname: Knudsen
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000378:metabolism*; D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects*; D020536:Enzyme Activators / Q000008:administration & dosage*; D006801:Humans; D050155:Lipogenesis / Q000187:drug effects*; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology*
chemical_list: D020536:Enzyme Activators; D055372:AMP-Activated Protein Kinases